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Prime editing for functional repair in
patient-derived disease models
Imre F. Schene1,2,3,9, Indi P. Joore2,3,9, Rurika Oka 4,5, Michal Mokry 1, Anke H. M. van Vugt1,3,
Ruben van Boxtel 4,5, Hubert P. J. van der Doef6, Luc J. W. van der Laan 7, Monique M. A. Verstegen7,
Peter M. van Hasselt2, Edward E. S. Nieuwenhuis1,8,10 & Sabine A. Fuchs 1,2,3,10✉
Prime editing is a recent genome editing technology using fusion proteins of Cas9-nickase
and reverse transcriptase, that holds promise to correct the vast majority of genetic defects.
Here, we develop prime editing for primary adult stem cells grown in organoid culture
models. First, we generate precise in-frame deletions in the gene encoding β‐catenin
(CTNNB1) that result in proliferation independent of Wnt-stimuli, mimicking a mechanism of
the development of liver cancer. Moreover, prime editing functionally recovers disease-
causing mutations in intestinal organoids from patients with DGAT1-deficiency and liver
organoids from a patient with Wilson disease (ATP7B). Prime editing is as efficient in 3D
grown organoids as in 2D grown cell lines and offers greater precision than Cas9-mediated
homology directed repair (HDR). Base editing remains more reliable than prime editing but is
restricted to a subgroup of pathogenic mutations. Whole-genome sequencing of four prime-
edited clonal organoid lines reveals absence of genome-wide off-target effects underscoring
therapeutic potential of this versatile and precise gene editing strategy.
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The development of gene-editing therapies to treat mono-genic diseases has long been an essential goal of CRISPR/Cas9 research. Cas9-mediated homology-directed repair
(HDR) can create all desired base substitutions, insertions and
deletions (indels). However, HDR relies on introduction of
double-stranded DNA breaks, is inefficient and error-prone1,2.
Base editing, that uses Cas9-nickases fused to DNA-modifying
enzymes, is more efficient and accurate than HDR, but can only
correct four out of twelve nucleotide substitutions and no small
insertions and deletions. Furthermore, base editing requires a
suitable protospacer adjacent motif (PAM) and the absence of co-
editable nucleotides3.
Prime editing combines a nicking-Cas9–reverse transcriptase
fusion protein (PE2) with a prime editing guide RNA (pegRNA)
containing the desired edit. The pegRNA-spacer guides the Cas9-
nickase to create a nick in the targeted DNA strand. The
pegRNA-extension binds to this nicked strand and instructs the
reverse transcriptase to synthesize an edited DNA flap. This
edited flap is then integrated by DNA repair mechanisms, which
can be enhanced by simultaneous nicking of the non-edited
strand (Supplementary Fig. 1)4.
Prime editing has been applied in human cell lines, plant cells,
and mouse embryonic cells but not in human disease models4–7.
Adult stem cell-derived organoids exhibit important functional
properties of organs, allowing modeling of monogenic diseases8.
In this work, we develop prime editing in primary patient-
derived organoids to show functional correction of disease-
causing mutations and generation of representative disease
models. We find that prime editing in 3D organoids is as efficient
as in 2D cell lines and does not result in detectable genome-wide
off-target effects.
Results
Prime editing efficiently creates mutations in organoids. We
first optimized prime editing for organoid cells using deletions
and single-nucleotide substitutions previously performed in
HEK293T cells4. The non-edited strand was nicked by a second
“nicking sgRNA” to enhance editing (PE3). Our optimized pro-
tocol consisted of co-transfection of prime edit plasmids with a
GFP-reporter plasmid allowing selection and subsequent clonal
expansion of transfected cells. Prime editing of intestinal and
ductal liver organoids resulted in efficient deletion of five
nucleotides in HEK3, with the majority of picked clones con-
taining monoallelic or biallelic deletions (Fig. 1b and Supple-
mentary Fig. 2)4. Furthermore, we were able to induce a
transversion mutation located 26 nucleotides downstream of the
nick in 20% of the clones (Fig. 1c)4.
Next, we targeted the Wnt-pathway intermediate β‐catenin
(CTNNB1) in organoids. Activating carcinogenic CTNNB1
mutations are found in ±40% of hepatocellular carcinoma,
resulting in Wnt-signaling independent of exogenous stimuli9.
We designed PE3 plasmids, containing pegRNA-extensions with
primer binding sites (PBSs) and RT-templates of various lengths,
that all create in-frame deletions in the β-TrCP region required
for CTNNB1 ubiquitination (Fig. 1d). As wildtype liver organoid
expansion depends on Wnt-pathway activation, edited cells could
be selected by withdrawing Wnt-agonist R-spondin 1 (Fig. 1e).
Sequencing confirmed that all clones grown without R-spondin
for 2 weeks contained heterozygous in-frame deletions in
CTNNB1 (Fig. 1f and Supplementary Fig. 2c). We observed
striking differences (up to a factor 50) in editing efficiencies of
different pegRNA designs (Fig. 1g). Next, we generated the severe
ABCB11D482G mutation, a frequent cause of bile salt export pump
(BSEP) deficiency10. This nucleotide substitution was generated
in 20% of the liver organoid clones when silent PAM mutations
were introduced (Supplementary Fig. 3). These results demon-
strate the utility of prime editing in creating disease models and
the importance of testing different pegRNA designs to induce the
desired edit.
To examine the efficiency and byproduct formation of prime
editing in primary stem cells, we performed high-throughput
sequencing of two targeted amplicons (HEK3 and CTNNB1). The
desired edit was installed with 30–50% efficiency, while unwanted
byproducts at the pegRNA or nickase sgRNA target sites only
occurred at a rate of 1–4% in liver- and intestine-derived
organoid cells. These rates were similar in two-dimensional
HEK293T and Caco-2 cell lines from the same experiment
(Fig. 1h). Distinct byproducts were shared between organoid lines
and 2D cell cultures, suggesting that the mechanism of byproduct
formation is independent of culture type (Supplementary Fig. 4).
Together, these results show successful prime editing of primary
stem cells with similar efficiency and accuracy as in human cancer
cell lines.
Prime editing functionally corrects disease-causing mutations.
To investigate prime editing for functional correction of disease-
causing mutations, we studied diacylglycerol-acyltransferase 1
(DGAT1) in patient-derived intestinal organoids. DGAT1
encodes an enzyme catalyzing the conversion of diacylglycerol
and fatty acyl-CoA to triacylglycerol. When DGAT1 function is
deficient, fatty acids (FAs) cannot be incorporated in lipid
droplets and instead cause lipotoxicity and cell death (Fig. 2a).
DGAT1 mutations result in congenital diarrhea and protein-
losing enteropathy upon lipid intake11. The common biallelic 3-
bp deletion (c.629_631delCCT, p.S210del) in exon 7 of DGAT1
leads to complete absence of the mature protein (Fig. 2b, e)11.
We designed PE3 plasmids to promote the insertion of the
missing three nucleotides. These plasmids were transfected into
patient-derived organoid cells and organoids were grown from
single transfected cells. PE3 plasmids did not reduce the out-
growth efficiency or proliferation capacity of organoid cells,
relative to a GFP plasmid only control (Supplementary Fig. 5a).
Sanger sequencing of clonal organoids revealed repair of the
pathogenic deletion (Fig. 2b). To demonstrate DGAT1 function
of prime-edited cells, we exposed organoids to FAs, which are
harmless to healthy control organoids and toxic to DGAT1-
deficient organoids (Fig. 2c, d and Supplementary Fig. 5b). All
clones surviving functional selection were genetically repaired
(Fig. 2c and Supplementary Fig. 6a) and showed normal DGAT1
protein expression (Fig. 2e and Supplementary Fig. 6c). Next, we
compared prime editing with HDR in terms of efficiency and
accuracy. The ratio of correct editing to unwanted indels was
±30-fold higher for prime editing than for Cas9-initiated HDR
(Fig. 2f and Supplementary Fig. 6d). These findings show that
prime editing, as opposed to base editing, can repair small
deletions with considerably higher precision and efficiency than
HDR.
To compare prime editing to base editing, we selected two
severe pathogenic G→ A mutations suitable for correction by
adenine base editors (ABEs): the BSEP-deficiency mutation
ABCB11R1153H and the alpha-1 antitrypsin deficiency ZZ-
genotype (SERPINA1E342K)10,12,13. Without pegRNA design
optimization, prime editing was outperformed by base editing
in efficiency (Fig. 2g and Supplementary Fig. 7), indicating that
the added value of prime editing currently lies in correcting
mutations that are uneditable by base editors.
Next, we set out to repair a 1-bp duplication (c.1288dup,
p.S430fs) in ATP7B, causing Wilson disease. ATP7B encodes a
copper-transporter (ATP7B), facilitating excretion of excess
copper into the bile canaliculus (Fig. 2h). Pathological
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accumulation of copper in the liver of Wilson disease patients
leads to liver cirrhosis requiring lifelong treatment and ultimately
liver transplantation14. We designed several PE3 conditions to
remove the 1-bp duplication in patient-derived liver organoids
(Supplementary Fig. 9). Clonal picking of transfected organoid
cells confirmed monoallelic repair of the disease-causing muta-
tion by pegRNA#2 (Fig. 2i). We then generated ATP7BKO
organoids that were more susceptible to copper-induced cell
death than ATP7BWT organoids (Fig. 2j and Supplementary
Fig. 7). To demonstrate functional repair of ATP7BS430fs
a
b
c
h
d
f g
e
Fig. 1 Prime editing efficiently creates deletions and point mutations in organoids. a Schematic overview of the workflow and timeline to generate
precise mutations in organoid cells using prime editing (PE3). b pegRNA design, Sanger validation in a clonal organoid with monoallelic edit, and editing
efficiency of a 5-bp deletion in HEK3 in liver and intestinal organoids. c pegRNA design, Sanger validation of monoallelic edit, and editing efficiency for a
C→G substitution in HEK3 in liver organoids. Nicking sgRNA at +90 used in b and c not shown. d pegRNA designs for the generation of in-frame deletions
in the β-TrCP region of CTNNB1. Nicking sgRNA at +86 (S1) or +93 (S2) not shown. e Brightfield images of liver organoid cells transfected with plasmids
from d after Rspo1 withdrawal for 2 weeks. White scale bars are 500 µm. f Sanger validation of precise 6-bp deletions in all picked clones from CTNNB1
pegRNA S1E1 that continue growing in -Rspo1 conditions. g Quantification of organoid outgrowth in e. p < 0.0001 in a one-way ANOVA with Holm–Sidak
correction. h Comparison of editing efficiencies and generation of unwanted byproducts in different cell types by high-throughput sequencing (HTS). Only
transfected cells (GFP+ sorted) were used for HTS. Data are represented as mean values ±S.D. of three independent experiments g or biological replicates
h. FA fatty acids, PBS primer binding site, RTT reverse transcriptase template, NC negative control. Source data are provided as a Source Data file.
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organoids after prime editing, transfected cells were exposed to
copper for 4 days (Supplementary Fig. 2). Out of three different
pegRNA plasmids, only successful monoallelic repair with
pegRNA#2 resulted in rescue of copper excretion (Fig. 2k). These
results confirm the ability of prime editing to genetically and
functionally correct truncating mutations and underline the
importance of testing various pegRNA designs.
Prime editing induces no genome-wide off-target effects. The
rate at which genome editors generate undesired mutations across
the genome is a major determinant of their therapeutic potential.
To date, no genome-wide examination of the fidelity of prime
editors has been conducted in human cells. We therefore per-
formed whole-genome sequencing (WGS) analysis on two prime-
edited clones and their respective unedited control clones for both
the CTNNB1 6-bp deletion in liver organoids and the DGAT1 3-
bp insertion in intestinal organoids. To identify possible variants
induced by prime editing, mutational profiles of clones were
background-corrected for variants already present in the donor
bulk culture (Fig. 3a). At in silico predicted off-target sites
(204 and 287 for CTNNB1 and DGAT1 edits, respectively) no
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Fig. 2 Prime editing functionally corrects disease-causing indel mutations in intestinal and liver organoids. a Schematic overview of the DGAT1 disease
mechanism. b Sanger validation of biallelic DGAT1S210del mutations in patient-derived intestinal organoids, pegRNA design (nicking sgRNA at position +46
not shown), and Sanger validation of successful biallelic correction by PE3. c Brightfield images of healthy control- and DGAT1S210del patient-derived
intestinal organoids (±PE3) after exposure to 4mM OA for 24 h and subsequent passaging (split). White scale bars are 500 µm. Quantification of
corrected alleles in patient organoids after PE3 and OA selection; all surviving organoids are gene-corrected. d Quantification of DGAT1S210del patient
organoid survival upon exposure to 4mM OA, after targeting with different PE3 or PE3b plasmids. Data are represented as mean ±S.D. of three
independent experiments in two different donors. e Western blot of DGAT1 in DGAT1S210del, healthy control, and PE3-corrected DGAT1S210del organoids.
f, Quantification of correct edits and unwanted indels by PE3 and Cas9-initiated HDR in DGAT1S210del organoids. Note that no functional selection with OA
was performed prior to quantification. g Comparison of PE3 and adenine base editing (ABEmax-NG) to correct the ABCB11R1153H and SERPINA1E342K
mutations in liver organoids from patients with BSEP-deficiency and alpha-1-antitrypsin deficiency, respectively. h Schematic overview of the Wilson
disease (ATP7B deficiency) mechanism. i Sanger validation of biallelic ATP7BS430fs mutations in patient-derived liver organoids, pegRNA#2 design to
target this mutation, and Sanger validation of successful monoallelic correction by PE3. j Cell death in ATP7BWT and ATP7BKO liver organoids after
incubation with Cu2+ for 3 days. n= 2 biologically independent samples for both WT and KO groups. k Brightfield images of ATP7BS430fs-patient organoid
survival upon exposure to 0.25 mM Cu2+ for 3 days, after transfection with different PE3 plasmids. “at −39” stands for nicking sgRNA at position −39.
Note that only prime editing using pegRNA#2 yields functional correction of ATP7B (white arrowheads). White scale bars are 500 µm. ER endoplasmic
reticulum, FFA free fatty acid, Ex exon, NC negative control, OA oleic acid, PE3+ m PE3 with introduction of PAM mutation, HDR homology-directed repair,
ABE adenine base editor, PI propidium iodide. Source data are provided as a Source Data file.
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mutations occurred in a range of 200 bp in any of the prime-
edited clones (Supplementary Table 4). The total number of new
base substitutions or indels was not higher in prime-edited clones
compared to controls (Fig. 3b). Specifically, no additional 6-bp
deletions or 3-bp insertions appeared (Supplementary Table 4).
Furthermore, no clustering of new mutations on a genome-wide
scale, known as mutational hotspots, was present in any of the
samples (Supplementary Fig. 10b).
Ongoing mutational accumulation during cell culture prevents
direct attribution of specific mutations to prime editing. We
therefore applied mutational signature analysis to search for
mutational patterns due to potential aberrant prime editor
activity15,16. The mutational signatures of prime-edited clones
and unedited negative controls (NCs) were highly similar, both
resembling the signature that arises during long-term propaga-
tion of intestinal organoids in vitro (Fig. 3c)15. Signatures of NCs
and prime-edited samples could be reconstructed to a comparable
degree by the combination of known in vivo- and in vitro
mutational signatures (cosine similarity 0.92–0.96; Fig. 3d and
Supplementary Fig. 10c). This indicates that prime editors do not
leave a mutational fingerprint at the genome-wide scale. Safety of
prime editing was further confirmed by absence of additional
oncogenic mutations in tumor suppressor genes or oncogenes
compared to negative controls, apart from the intended 6-bp
deletion in CTNNB1 samples (Supplementary Fig. 10d)17.
Discussion
Versatile, efficient, and safe gene editing in primary cells repre-
sents a gamechanger for both in vitro modeling of monogenetic
diseases and treatment with autologous gene-corrected cells.
Here, we provide a protocol for effective prime editing in human
adult stem cells. Using this protocol, we demonstrate that prime
editing can generate insertions, deletions, and various point
mutations and functionally correct disease phenotypes in patient-
derived stem cells. We find high editing rates and low byproduct
formation in both 3D-cultured adult stem cell organoids and 2D-
cultured cancer cell lines. Importantly, prime editing results in
higher efficiency and drastically lower indel-formation compared
with Cas9-mediated HDR. In the subset of mutations applicable
to base editing, prime editors are currently less robust than the
latest generation of base editors.
Our data in primary adult stem cells corroborate findings in
cancer cell lines and mouse cortical neurons, in which prime
editing typically offers greater precision than Cas9-mediated
HDR and lower on-target efficiency than base editing, when the
target nucleotide is suitably located4. Base editing, however, has
been subject to various stages of optimization, whereas prime
editing is still in its infancy13,18,19. The efficiency of prime editing
in mammalian and plant cells has been strongly associated with
pegRNA design, but optimal PBS and RT-template parameters
remain elusive and differ between target sites4,6,7. In our hands,
pegRNA design also had profound effects on editing efficiency,
with PBS lengths of 10–12 nucleotides outperforming longer
designs (Figs. 1g and 2k). We expect that pegRNA design as well
as the prime editor fusion protein can be further optimized to
improve prime editing efficiency in the future.
The WGS analysis provided here constitutes the most com-
prehensive genome-wide interrogation of prime editor fidelity to
date. We did not find any off-target effects at locations resembling
the target site. Neither could we identify a mutational signature
induced by prime editor enzymes. Despite our small sample size,
this absence of genome-wide off-target effects is reassuring for
further therapeutic development.
To conclude, this study confirms the potential of prime editing
to model and safely repair human monogenic diseases and
represents an important step towards future clinical application.
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Fig. 3 Prime editing induces no genome-wide off-target effects. a Schematic overview of the protocol used to identify mutations induced by prime editing
(PE3). WGS was performed for one unedited negative control and two prime-edited clonal lines for both DGAT1 (intestinal organoids) and CTNNB1 (liver
organoids). b Total number of single-nucleotide variants (SNVs) and insertions and deletions (indels) in control (NC) and prime-edited (PE3) clonal
organoid lines (n= 2 and n= 4 biologically independent samples, respectively). Error bars represent S.D. c Mutational signature analysis by relative
contribution of context-dependent mutation types in an in vivo (n= 6) and in vitro (n= 6) data set (Blokzijl et al.16) and in control and prime-edited clonal
organoid lines. d Relative contribution of known in vivo and in vitro mutational signatures from Blokzijl et al.16 in control (NC) and prime-edited (PE3) clonal
organoid lines (n= 2 and n= 4 biologically independent samples, respectively). Dotted line at 0.9 indicates highly accurate signature reconstruction. NC
negative control, WGS whole-genome sequencing.
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Methods
Study approval and human subjects. The study was approved by the responsible
local ethics committees (Institutional Review Board of the University Medical
Center Utrecht (STEM: 10-402/K) and Erasmus MC Medical Ethical Committee
(MEC-2014-060). Tissue biopsies from liver of a patient with BSEP-deficiency was
obtained during a liver transplant procedure in the UMCG, Groningen, and
biopsies from duodenum of two patients with DGAT1-deficiency was obtained
during diagnostic duodenoscopy in the UMCG, Groningen.
Tissue biopsies from livers of patients with Wilson disease and alpha-1
antitrypsin deficiency were obtained during liver transplant procedures in the
Erasmus MC, Rotterdam. All biopsies were used after written informed consent.
Organoid culture. Liver and intestinal organoids were cultured and passaged
according to previously described protocols12,20. In short, liver organoids were
plated in matrigel (Corning) and maintained in liver expansion medium (EM),
consisting of AdDMEM/F12 (GIBCO) supplemented with 2% B27 without vitamin
A (GIBCO), 1.25 mM N-Acetylcysteine (Sigma), 10 mM Nicotinamide (Sigma),
10 nM gastrin (Sigma), 10% RSPO1 conditioned media (homemade), 50 ng/ml
EGF (Peprotech), 100 ng/ml FGF10 (Peprotech), 25 ng/ml HGF (Peprotech), 5 mM
A83-01 (Tocris), and 10 mM FSK (Tocris). SI organoids were plated in matrigel
and maintained in SI EM, consisting of AdDMEM/F12 supplemented with 50%
WNT3A-, 20% RSPO1-, and 10% NOG(gin)-conditioned medium (all home-
made), 2% B27 with vitamin A (GIBCO), 1.25 mM N-Acetylcysteine, 10 mM
Nicotinamide, 50 ng/ml murine-EGF (Peprotech), 500 nM A83-01, and 10 mM
SB202190 (Sigma). The medium was changed every 2–4 days and organoids were
passaged 1:4 –1:8 every week. After thawing, organoids were passaged at least once
before electroporation.
Plasmid cloning. Cloning of pegRNA plasmids was performed according to pre-
viously described protocols4. In brief, the pU6-pegRNA-GG-Vector (Addgene
#132777) was digested overnight with BsaI-HFv2 (NEB) and the 2.2 kb fragment
was isolated. Oligonucleotide duplexes containing the desired pegRNA spacer,
pegRNA extension, and pegRNA scaffold sequences were ordered with the
appropriate overhangs and annealed. Annealed pegRNA duplexes were cloned into
the pU6-pegRNA-GG-Vector using Golden Gate assembly with BsaI-HFv2 (NEB)
and T4 DNA ligase (NEB) in a protocol of 12 cycles of 5 min at 16 °C and 5min at
37 °C. For cloning of sgRNAs used for PE3 and ABE-NG, we replaced the BsmBI
restriction sites of the sgRNA expression vector BPK1520 by BbsI restriction sites
using PCR, which allowed direct ligation of sgRNA-spacer duplexes21. All pegRNA,
sgRNA, HDR template, and primers sequences used in this work are listed in
Supplementary Tables 1–3 and were synthesized by Integrated DNA Technologies.
pCMV-PE2 (Addgene #132775), pU6-pegRNA-GG-acceptor (Addgene #132777),
and NG-ABEmax (Addgene #124163) were gifts from David Liu; BPK1520
(Addgene #65777) was a gift from Keith Joung; pSpCas9(BB)-2A-Puro (PX459,
Addgene #62988) was a gift from Feng Zhang.
Electroporation. Before electroporation, organoids were grown under normal con-
ditions in 30 µl Matrigel per well. Two days prior to electroporation, organoids were
cultured in medium containing surrogate WNT protein (4 nM). Four wells containing
organoids were then dissociated for each condition using TrypLE for 4–5min at 37 °C
and applying mechanical disruption through pipetting. Cells were washed once using
Advanced DMEM/F12, resuspended in 80 µl OptiMEM containing Y-27632 (10 µM),
and 20 µl DNA mixture was added. For prime editing, the DNA mixture contained
12 µg PE2 plasmid, 5 µg pegRNA plasmid, 2 µg nicking sgRNA plasmid, and 1 µg
GFP plasmid. For HDR, the DNA mixture contained 15 µg sgRNA containing-Cas9
plasmid (PX459), 1 µl of 100 µM HDR template, and 1 µg GFP plasmid. For base
editing, the DNA mixture contained 15 µg NG-ABEmax plasmid, 4 µg sgRNA plas-
mid, and 1 µg GFP plasmid. For generation of ATP7B knockout organoids, the DNA
mixture contained 15 µg sgRNA containing-Cas9 plasmid (PX459) and 1 µg GFP
plasmid. The cell-DNA mixture was transferred to an electroporation cuvette and
electroporated using a NEPA21 electroporator (NEPA GENE) with 2× poring pulse
(voltage: 175 V, length: 5ms, interval: 50ms, polarity: +) and 5× transfer pulse
(voltage: 20 V, length: 50ms, interval: 50ms, polarity ±), as previously described22.
Cells were removed from the cuvette and transferred into 500 µl OptiMEM con-
taining Y-27632 (10 µM). After 20min, cells were plated in 180 µl matrigel. Upon
polymerization of the Matrigel, medium was added containing surrogate WNT
protein (4 nM) and Y-27632 (10 µM).
Fluorescence-activated cell sorting (FACS). After 2–3 days of electroporation
using the GFP plasmid, cells were dissociated with TrypLE for 2–3 min at 37 °C.
The cells were washed once using Advanced DMEM/F12 and resuspended in
400 µl fluorescence-activated cell sorting (FACS) buffer (phosphate-buffered saline
with 2 mM ethylenediaminetetraacetic acid and 0.5% bovine serum albumin).
FACS was used to filter the GFP+ cell population, selecting specifically for
transfected cells (FACS Aria, BD). GFP+ cells were retrieved in medium con-
taining surrogate WNT protein (4 nM) and Y-27632 (10 µM), after which the cells
were plated as soon as possible at a cell-concentration of ±300 cells per 30 µl
Matrigel. Upon polymerization of the Matrigel, medium was added containing
surrogate WNT protein (4 nM) and Y-27632 (10 µM).
Organoid reconstitution and proliferation. The number of organoids in each
condition were counted by an automated counting algorithm 7 days after seeding
single FACS-sorted cells. Organoid reconstitution was calculated as percentage of
(number of organoids at day 7/number of cells seeded at day 0). Organoid cell
proliferation was measured by quantification of average organoid size at day 7 after
seeding single cells. At measurements, organoids were incubated with 1 µM Cell-
Trace Calcein Green AM (Thermo Scientific) for 30 min and subsequently imaged
by an inverted Olympus IX53 epifluorescence microscope (Tokyo, Japan). Images
were analyzed using an automated organoid counting algorithm written in ImageJ
and average organoid size was calculated for each condition and normalized to the
control condition (GFP only).
Genotyping. Single organoids were picked using a p200 pipette and dissociated
using TrypLE for 2–3 min at 37 °C. Cells were resuspended in 30 µl Matrigel total
of which 20 µl was plated. DNA was extracted from the remaining 10 µl Matrigel
using the Zymogen Quick-DNA microprep kit according to manufacturer
instructions. Q5 high fidelity polymerase was used to amplify the genomic region of
interest. The PCR product was purified using the Qiagen PCR clean-up kit
according to manufacturer instructions. Resulting product was sent for Sanger
sequencing to the Macrogen Europe service EZSeq.
High-throughput DNA sequencing of genomic DNA samples. Genomic sites of
interest were amplified from genomic DNA samples and sequenced on an Illumina
MiSeq as previously described4. In brief, Illumina forward and reverse adapters
(Supplementary Table 3) were used for a first round of PCR (PCR1) to amplify the
genomic region of interest. In a second round of PCR (PCR2) each sample was
barcoded with unique Truseq DNA Index primers (Illumina). DNA concentration
was measured by fluorometric quantification (Qubit, ThermoFisher Scientific) and
sequenced on an Illumina MiSeq instrument according to the manufacturer’s
protocols. Sequencing reads were demultiplexed using MiSeq Reporter (Illumina).
Alignment of amplicon sequences to reference sequences was performed by Cas-
analyzer in HDR mode, using the unedited sequence as the reference sequence and
the desired sequence as HDR donor DNA sequence23. Prime editing efficiency was
calculated as the percentage of (number of reads with the desired edit/number of
total aligned reads). For unwanted byproduct analysis at the pegRNA or nickase
sgRNA site, a comparison range (R) of 30 bp was used so that 60 bp flanking the
predicted nicking site were considered. Frequency of byproducts was calculated
as the percentage of (number of reads with unwanted edits/number of total
aligned reads).
Protein blotting. Organoids were lysed in Laemmli buffer (0.12 M Tris-HCl pH
6.8, 4% SDS, 20% glycerol, 0.05 g/l bromophenol blue, 35 mM β-mercap-
toethanol). Protein concentration was measured using a BCA assay. For western
blotting, equal amounts of protein were separated by SDS-PAGE on a 10%
acrylamide gel and transferred to polyvinylidene difluoride (PVDF) membranes
using a Trans-Blot® Turbo machine (Bio-rad) according to manufacturer’s
protocol. For dot blotting, protein was directly loaded on PVDF membranes
without SDS-PAGE separation. The membrane was blocked with 5% milk
protein in tris-buffered saline with Tween 20 (0.3% Tween, 10 mM Tris-HCl pH
8 and 150 mM NaCl in distilled water) and probed with primary antibodies
against DGAT1 (ab181180; 1:000; Abcam) or ACTB (sc-47778; 1:5000, Santa
Cruz Biotechnology) overnight at 4 °C. After incubation with horseradish per-
oxidase (HRP)-conjugated secondary antibodies (1:5000, DAKO p0260 and
p0217, 1 h at RT), bands or dots were imaged on a chemiluminescence detection
system (Bio-rad).
Functional assays. To select liver organoids with in-frame mutations in CTNNB1,
organoids were cultured in normal culture medium without R-spondin 1 for
2 weeks. To test DGAT1 function in intestinal organoids, 4 mM oleic acid was
added to the culture medium for 24 h and organoid survival was assessed by visual
inspection and survival after passaging. To test ATP7B function in liver organoids,
copper(II)chloride (CuCl2) was added to the culture medium for 3–4 days. Cell
death was quantified by addition of propidium iodide (PI) (0.1 mg/mL, Thermo-
Fisher) to the culture medium for 15 min. Organoids were imaged by an inverted
Olympus IX53 epifluorescence microscope. PI signal was quantified using ImageJ
and normalized to a positive control condition for cell death (1 mM CuCl2). Based
on ATP7BKO lines, prolonged organoid survival in 0.25 mM CuCl2 was considered
as a characteristic of functional ATP7B.
WGS and mapping. Genomic DNA was isolated from ±5 × 105 cells using the
Zymogen Quick-DNA microprep kit according to manufacturer’s instructions.
Standard Illumina protocols were applied to generate DNA libraries for Illumina
sequencing from 20 to 50 ng of genomic DNA. All samples (two genetically cor-
rected clones, one non-corrected control sample, and one “bulk” samples from the
starting culture for both the CTNNB1 6-bp-deletion and DGAT1 3-bp-insertion)
were sequenced (2 × 150 bp) using Illumina NovaSeq to 30× base coverage. Reads
were mapped against human reference genome hg19 using Burrows-Wheeler
Aligner v0.5.924 with settings “bwa mem -c 100 -M”. Duplicate sequence reads
were marked using Sambamba v0.4.7.32 and realigned per donor using Genome
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Analysis Toolkit (GATK) IndelRealigner v2.7.2 and quality scores were recalibrated
using the GATK BaseRecalibrator v2.7.2. More details on the pipeline can be found
on Github25.
Mutation calling and filtering. Raw variants were multisample-called by using the
GATK HaplotypeCaller v3.4–4626 and GATK- Queue v3.4–46 with default settings
and additional option “EMIT_ALL_CONFIDENT_SITES”. The quality of variant
and reference positions was evaluated by using GATK VariantFiltration v3.4–46
with options “-snpFilterName LowQualityDepth -snpFil- terExpression “QD < 2.0”
-snpFilterName MappingQuality -snpFilterExpression “MQ< 40.0” -snpFilter-
Name StrandBias - snpFilterExpression “FS > 60.0” -snpFilterName Haploty-
peScoreHigh -snpFilterExpression “HaplotypeScore > 13.0” -snpFilter- Name
MQRankSumLow -snpFilterExpression “MQRankSum < 12.5” -snpFilterName
ReadPosRankSumLow -snpFilterExpression “ReadPosRankSum <8.0” -cluster 3
-window 35”. To obtain high-quality somatic mutation catalogs, we applied post
processing filters as described16. Briefly, we considered variants at autosomal
chromosomes without any evidence from a paired control sample (“bulk” starting
culture); passed by VariantFiltration with a GATK phred-scaled quality score R
250; a base coverage of at least 20× in the clonal and paired control sample; no
overlap with single-nucleotide polymorphisms in the Single Nucleotide Poly-
morphism Database v137.b3730; and absence of the variant in a panel of unmat-
ched normal human genomes (BED-file available upon request). We additionally
filtered base substitutions with a GATK genotype score (GQ) lower than 99 or 10
in the clonal or paired control sample, respectively. For indels, we filtered variants
with a GQ score lower than 99 in both the clonal and paired control sample and
filtered indels that were present within 100 bp of a called variant in the control
sample. In addition, for both SNVs and INDELs, we only considered variants with
a mapping quality score of 60 and with a variant allele frequency of 0.3 or higher in
the clones to exclude in vitro accumulated mutations16. The scripts used are
available on Github27. The distribution of variants was visualized using an in house
developed R package (MutationalPatterns)16.
In silico off-target prediction. Potential sgRNA specific off-target events were
predicted using the Cas-OFFinder open recourse tool28. All potential off-targets up
to four mismatches were taken into account.
Mutational signature analysis. We extracted mutational signatures and estimated
their contribution to the overall mutational profile as described using an in house
developed R package (MutationalPatterns)16. In this analysis, we included small
intestine data (previously analyzed)15 to explicitly extract in vivo and in vitro
accumulated signatures16.
Statistics and reproducibility. No pre-specified effect size was calculated, and no
statistical method was used to predetermine sample size. The source data for
figures can be found in the Source Data file. For comparisons of multiple groups,
an ordinary one-way analysis of variance with Holm–Sidak correction for multiple
comparisons was used and performed in Prism (GraphPad Software). All graphs
were plotted using Prism (GraphPad Software). In Figs. 1g and 2d the negative
control and the healthy control, respectively, were excluded from statistical com-
parisons. Statistical tests were appropriate for comparisons being made; assessment
of variation was carried out but not included. Experiments were not randomized.
Investigators were not blinded to allocation during experiments but outcome
assessment (sequencing and functional assay quantification) were performed
blinded. Reproducibility: Fig. 1b representative of 12 and 10 clonal liver and
intestinal organoids, respectively, each from two independent transfection experi-
ments. Figure 1c, f representative of 10 clonal liver organoids, from two and three
independent transfection experiments, respectively. Figure 1g representative of
three transfection experiments using the same liver organoid donor. Figure 1h
representative of three biological replicates from one transfection experiment.
Figure 2c representative of 20 clonal organoids from two independent experiments.
Figure 2d representative of three independent transfection experiments in two
different donors. Figure 2e and Supplementary Fig 6c represent a single blotting
experiment. Figure 2f representative of 24 and 32 clonal organoids from two
independent experiments. Figure 2g representative of 10 clonal liver organoids per
condition, collected through two independent experiments. Figure 2j represents a
single experiment. Figure 2k representative of two experiments. Figure 3 and
Supplementary Fig. 10 represent a single experiment with two edited clones and
one negative control for each of two prime edits. Supplementary Fig. 3 repre-
sentative of 30 clonal liver organoids from two independent experiments. Sup-
plementary Fig. 5b are representative images for three independent transfection
experiments.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Code availability
Cas-Analyzer is publicly available [http://www.rgenome.net/cas-analyzer]. The
algorithms used for mapping [https://github.com/UMCUGenetics/IAP], mutational
calling [gatk.broadinstitute.org], mutational filtering [https://github.com/ToolsVanBox/
SMuRF], and mutational pattern analysis [https://www.bioconductor.org/packages/
release/bioc/html/MutationalPatterns.html] of WGS data are all publicly available. Cas-
OFFinder was used for in silico prediction of off-target sites of pegRNA and sgRNA
spacers and is available at [http://www.rgenome.net/cas-offinder/]. The algorithms to
quantify the number and size of organoids, as well as to quantify the signal of propidium
iodide, were written in ImageJ and are available from the corresponding author on
reasonable request.
Data availability
Source data for the figures have been provided as a Source Data file. The WGS samples of
Fig. 3 and Supplementary Fig. 10 have been submitted to the European Genome-
phenome Archive under study number EGAS00001004611. All other data and material
supporting the findings of this study are available from the corresponding author on
reasonable request. Source data are provided with this paper.
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